Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Biovitrum, Syntonix Begin Trial With Hemophilia Treatment
RxTrials Institute Drug Pipeline Alert
March 12, 2008 | Vol. 6 No. 11
Biovitrum, Syntonix Begin Trial With Hemophilia Treatment
Swedish drugmaker Biovitrum and its U.S. partner Syntonix have obtained permission from the FDA to begin a Phase I/II trial of IV recombinant Factor IX (FIXFc) for patients with hemophilia B.
The extended half-life of the product could enable effective treatment for both prophylaxis and on-demand therapy because it requires fewer IV injections than other drugs.
The market potential for Factor IX products is estimated to be more than $600 million annually, according to Biovitrum.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.